SPRY ARS Pharmaceuticals, Inc.: institutional ownership and insider trading
220 funds reported holding $782M of ARS Pharmaceuticals, Inc. in their latest 13F filings; in Q2 2026 funds net sold $27.4M, with 35 new positions and 31 funds selling out; over the last 12 months insiders bought $0 and sold $1.95M on the open market.
Famous investors holding SPRY
- Dan Loeb (Third Point): $8.01M, 0.2% of the portfolio
- Izzy Englander (Millennium Management): $20.2M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $4.54M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $420K, 0.0% of the portfolio
Largest institutional holders of SPRY
- RA CAPITAL MANAGEMENT, L.P. — $87.0M
- Rubric Capital Management LP — $68.4M
- ORBIMED ADVISORS LLC — $66.4M
- DEERFIELD MANAGEMENT COMPANY, L.P. — $60.1M
- BlackRock, Inc. (BLK) — $42.5M
- VANGUARD GROUP INC — $40.9M
- Tyro Capital Management LLC — $35.7M
- Aberdeen Group plc — $33.4M
- SR ONE CAPITAL MANAGEMENT, LP — $32.1M
- STATE STREET CORP (STT, STT-PG) — $29.9M
Recent SPRY insider trades
- Jun 12, 2026: Fitzpatrick Alexander A sold 3,355 shares ($33.6K)
- Jun 12, 2026: Karas Eric sold 25,000 shares ($250K)
- Nov 13, 2025: Dorsey Brian sold 21,828 shares ($190K)
- Nov 12, 2025: Chakma Justin sold 166,380 shares ($1.48M)
5%+ owners
- Rubric Capital Management LP: 8.1% (Schedule 13G/A, filed May 15, 2026)
- BlackRock, Inc.: 5.3% (Schedule 13G, filed Jul 27, 2026)